Vor Biopharma Inc. (VOR) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 1.21
30Y Low0.8·High2.0
ROE
↓
N/A
—
5yr avg: -61.2%
30Y Low-155%·High-39%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VOR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Vor Biopharma Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $97M | $129M | $76M | $151M | $263M | $432M | — | — | — |
| Enterprise Value | $-296914464 | $-264361993 | $26M | $155M | $244M | $330M | — | — | — |
| P/E Ratio → | -0.20 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 0.79 | 1.00 | 1.05 | 2.00 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VOR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
VOR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -94.5% | -58.7% | -39.5% | -52.1% | -155.0% | -2483.2% | — |
| ROA | -229.3% | -229.3% | -66.3% | -46.3% | -34.0% | -43.3% | -101.1% | -200.1% | -412.3% |
| ROIC | — | — | -90.2% | -48.9% | -40.5% | -78.1% | -338.8% | — | — |
| ROCE | -132.0% | -132.0% | -76.1% | -52.5% | -36.0% | -46.3% | -118.3% | -2386.5% | — |
VOR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $396M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.33 | 0.24 | 0.16 | 0.08 | 0.38 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.52 | 0.03 | -0.07 | -0.47 | -0.63 | -0.85 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -16.83 | -3.14 |
Net cash position: cash ($396M) exceeds total debt ($3M)
VOR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Vor Biopharma Inc.'s current ratio of 18.20x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 9.04x to 18.20x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.20 | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 | 3.45 | 0.12 |
| Quick Ratio | 18.20 | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 | 3.45 | 0.12 |
| Cash Ratio | 18.08 | 18.08 | 4.94 | 8.81 | 17.55 | 20.43 | 4.76 | 2.96 | 0.12 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
VOR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Vor Biopharma Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $10M | $3M | $3M | $2M | $2M | $2M | $2M | $283024 |
Peer Comparison
Compare VOR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VORYou | $97M | -0.2 | — | — | — | — | — | — | — |
 BEAM | $3B | -36.3 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -7.8 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $239M | -1.4 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 NTLA | $1B | -3.2 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 FATE | $230M | -1.7 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 CELC | $4B | -23.7 | — | — | — | — | -163.8% | -80.4% | — |
 SANA | $771M | -2.9 | — | — | — | — | -118.7% | -74.4% | — |
 SGMO | $62M | -0.3 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
 ILMN | $25B | 30.5 | 23.3 | 27.1 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 PACB | $419M | -0.7 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
What if you invested $1,000 in VOR 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in VOR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs VOR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationVOR vs BEAM — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Beam Therapeutics Inc..
Compare NowVOR — Frequently Asked Questions
Quick answers to the most common questions about buying VOR stock.
What is Vor Biopharma Inc.'s P/E ratio?
Vor Biopharma Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Is VOR stock overvalued?
Based on historical data, Vor Biopharma Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.